Journal
NATURE REVIEWS ENDOCRINOLOGY
Volume 19, Issue 7, Pages 377-378Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41574-023-00849-w
Keywords
-
Categories
Ask authors/readers for more resources
Type 1 diabetes mellitus (T1DM) can be predicted and altered by immune therapy. The FDA's approval of teplizumab as the first disease-modifying therapy for T1DM and delaying the clinical onset of any immune-mediated disease represents a paradigm shift in the treatment of T1DM.
Type 1 diabetes mellitus (T1DM) can be predicted, and immune therapy can alter the progression of the disease. The FDA's approval of teplizumab as the first disease-modifying therapy for T1DM and the first therapy aimed at delaying the clinical onset of any immune-mediated disease represents a paradigm shift in the treatment of T1DM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
